VDAC1 expression was also correlated with tumor progression and sensitivity to chemotherapy (Simamura et al. 2008; Pernemalm et al. 2013), whereas gene expression or proteomic analysis of NSCLC or primary lung adenocarcinoma patients revealed high VDAC1 expression levels as a predictor of poor outcome (Grills et al. 2011; Pernemalm et al. 2013). This evidence concerns the gene VDAC1 and lung adenocarcinoma.